| Three Extreme FDA Medical Device / Diagnostic Trades Mike Havrilla submits:Below is a selection of companies with stock prices below $5 per share and upcoming binary events in the form of FDA decisions for medical device /diagnostic submissions to the Agency. A common strategy used by many investors is to buy a basket of several small or micro-cap companies (generally less than $1 billion market cap stocks) with pending binary events approximately 3-6 months ahead of the expected catalyst date and sell into the expected upward momentum in both stock price and trading volume. Medical device and diagnostic submissions for FDA marketing clearance represent a unique niche within the space of trading binary events since there are no firm decision deadlines for decisions by the Agency and there is often a great deal of variability in the review periods. For example, Cambridge Medical (CAMH.OB) received marketing clearance for its Microvolt T-Wave Alternans OEM module used in cardiac stress testing systems in less than three months while other companies such as Nephros [NEPH.OB] ($0.54, $22 million market cap) have been waiting for over one year.Complete Story » seekingalpha.com |
National Dentex Completes Merger with GeoDigm, a Welsh, Carson, Anderson & Stowe Portfolio Company (Business Wire) NATICK, Mass.----National Dentex Corporation , one of the largest owner/operators of dental laboratories in North America, announced that earlier today its shareholders adopted and approved the Agreement and Plan of Merger among GDC Holdings, Inc., a Delaware corporation , Royal Acquisition Corp., a Delaware corporation and an indirect wholly owned subsidiary of Parent and a direct wholly owned subsidiary of GeoDigm Corporation, a Minnesota corporation , and National Dentex. us.rd.yahoo.com |
BioReference Laboratories, Inc. Announces Earnings Date for Third Quarter for Fiscal Year 2010 (Business Wire) ELMWOOD PARK, N.J.----BioReference Laboratories, Inc. announced today it plans to issue earnings results for the third quarter of fiscal 2010 before the open of market trading on Thursday, August 26, 2010. us.rd.yahoo.com |
Pfizer Is Not Paying a Ransom for King EP Vantage submits:Considering King Pharmaceuticals' (KG) share price has not been anywhere close to $14.25 in the last three years, Pfizer’s (PFE) takeover offer will look pretty tempting to a lot of the company’s shareholders. The bid announced Tuesday morning values King at $3.6bn, 40% more than the pain specialist’s market value Monday. The move makes sense given Pfizer’s significant presence in CNS, led by blockbusters Lyrica and Celebrex, but less so when considering King’s far from spotless progress over the last 18 months in getting new products to market. A move typical for a company that cannot help itself when it comes to acquisitions, perhaps, but hardly one that will lessen the Lipitor patent cliff. Complete Story » seekingalpha.com |
Insight Imaging Completes Acquisition of Virginia Imaging Center [Business Wire] - InSight Health Services Holdings Corp. today announced that it has completed the acquisition of a multi-modality imaging center in Roanoke, VA. The acquisition expands Insight Imaging’s presence in Virginia to four locations. us.rd.yahoo.com |